List view / Grid view
Former Senior Vice President, Head of Research and Product Development…
Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk…
Phase III trial shows Evusheld (tixagevimab and cilgavimab) significantly reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
The European Commission has approved Forxiga (dapagliflozin) for use in…
The European Commission has approved Forxiga (dapagliflozin) for use in the EU to treat symptomatic chronic heart failure with reduced ejection fraction.
The Phase I trial will assess the safety and pharmacokinetics…
The Phase I trial will assess the safety and pharmacokinetics of the AZD7442 monoclonal antibody combination in 48 healthy participants.
A new agreement between the University of Oxford and AstraZeneca…
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
Farxiga (dapagliflozin) has been given Fast Track designation by the…
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
Fast Track designation has been granted to Farxiga to prevent…
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
A clinical trial to study a chronic obstructive pulmonary disease…
A clinical trial to study a chronic obstructive pulmonary disease treatment has found that the drug is effective and safe.
AstraZeneca today announced that the European Medicines Agency’s Committee for…
AstraZeneca today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option for Fasenra (benralizumab) and a new delivery method as a pre-filled, single-use auto-injector (the Fasenra pen) to the medicine’s product information in the European…
AstraZeneca announced that Cambridge City Council has granted planning permission…
4 February 2015 | By AstraZeneca
AstraZeneca announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City...
AstraZeneca revealed the proposed designs for its new Global R&D…
18 July 2014 | By AstraZeneca
AstraZeneca revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK...
AstraZeneca announced that it has selected architects Herzog & de…
19 November 2013 | By AstraZeneca
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre...
